Each of our programs is guided by compelling genetics and a clear understanding of target mechanisms and their impact on disease. With our breakthrough computational platform we engineer selective and potent therapeutics that solve long-standing challenges, resulting in medicines with unprecedented potency, selectivity and pharmacokinetics.
Discoveries from the ‘omics revolution have produced hundreds of biologically important targets, many of which have proven unreachable by traditional small molecule drug development. Our diverse pipeline of first-in-class medicines comprises highly desirable disease targets in metabolic disease, oncology and inflammation that have proven inaccessable to traditional chemistry approaches.
We obliterate the boundaries between drug discovery, chemistry and pharmacology – and between Nimbus and our network of collaborators. Bolstered by our novel drug discovery platform and our unique business model, we are forging a broad spectrum of strategic collaborations to bring novel medicines to patients.
April 4, 2016
Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxylase (ACC) Program for NASH and Other Liver Diseases
February 2, 2016
Nimbus Therapeutics Granted Fast Track Designation for Its Allosteric ACC Inhibitor, NDI-010976, for the Treatment of NASH
© 2016 Nimbus Therapeutics